New drugs and dosage forms
- Combination Pill Approved for High Blood Pressure. // Journal of Gerontological Nursing;Nov2009, Vol. 35 Issue 11, p7
The article reports on the move of the U.S. Food and Drug Administration to approve the combination drug Valturna for treatment of high blood pressure. The drug is a combination of valsartan, the active ingredient in the blood pressure medication Diovan, and aliskiren, the active ingredient in...
- New drugs and dosage forms. // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788
The article offers information on the use of new drugs for specific treatments including dexamethasone intravitreal implant for noninfectious ocular inflammation, combination of drospirenone, ethinyl estradiol, and levomefolate calcium tablets and levomefolate calcium tablets for pre-menstrual...
- Natazia for contraception. // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.17
The article reports that the Food and Drug Administration (FDA) approved the use of estradiol valerate/dienogest tablets Natazia from Bayer Healthcare AG as oral contraceptive in the U.S.
- Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials*This paper is based on a Cochrane review published in the Cochrane Library, 2005 issue 3, (see www.thecochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review. A. Edelman; M.F. Gallo; M.D. Nichols; J.T. Jensen; K.F. Schulz; D.A. Grimes // Human Reproduction;Mar2006, Vol. 21 Issue 3, p573
BACKGROUND: With the recent US Food and Drug Administration approval of a combination oral contraceptive that causes a withdrawal bleed every 3 months instead of monthly, avoidance of menstruation through extended or continuous administration (>28 days of active pills) of combined oral...
- FDA actions. // Internal Medicine Alert;6/15/2013 Pharmacology Watch, p2
The article reports on the approval of the U.S. Food and Drug Administration (FDA) for a once-daily combination inhaler for the treatment of chronic obstructive pulmonary disease (COPD) which combines the long-acting beta-agonist (LABA) vilanterol with the steroid fluticasone furoate.
- FDA actions. Elliott, William T. // Infectious Disease Alert;Jul2013 Pharmacology watch, p2
The article reports on the approval made by the U.S. Food and Drug Administration (FDA) of a once-daily inhaler for treatment of chronic obstructive pulmonary disease (COPD) and a cholesterol combination drug, combining ezetimibe and atorvastatin.
- Netupitant--palonosetron combination approved by FDA. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/1/2014, Vol. 71 Issue 23, p2000
The article reports U.S. Food and Drug Administration's (FDA) approval of the marketing of netupitant-palonosetron capsules on October 10, 2014 for the prevention of nausea and vomiting associated with the receipt of cancer chemotherapy. The product, labelled as Akynzeo combines neurokinin-1...
- FDA approves four-drug anti-HIV combination tablet. Traynor, Kate // American Journal of Health-System Pharmacy;10/1/2012, Vol. 69 Issue 19, p1616
The article reports that the FDA approved a four-drug combination tablet Stribild, marketed by Gilead Sciences Inc. for the use in HIV-infected adults who have not previously undergone treatment for the infection. According to the FDA, the drug is a complete treatment regimen for HIV infection....
- FDA Update. // Oncology Nurse Advisor;May/Jun2014, Vol. 5 Issue 3, p15
No abstract available.